Research and Development Daily . . . The first type 1 liver and kidney syndrome drug was recommended and approved by an FDA panel of experts.

2020.07.16 Research and Development NEWS: Clinical results of Innovative Therapies for Alzheimer's Disease Actively Reduce Nerve Inflammation in Important Brain Tissues by 40%, Clinical Results of Innovative Therapy for Alzheimer's Disease Actively Reduce Seduria Neuroinflammation in Important Brain Tissues by 40%, and Drey Medical 2 Medical Device Products Were CE-Certified by the European Union... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original text) (drug research and development) Clinical results of the innovative therapy for Alzheimer's disease actively reduce nerve inflammation in important brain tissue by 40%, INmune Bio announced that its main candidate drug XPro1595, in Phase 1b clinical trials, significantly reduce nerve inflammation in Alzheimer's patients.
XPro1595 is a new generation of inhibitors of tumor necrosis, selectively neutralising the function of soluble TNF without affecting transmembrane TNF or TNF receptors.
The International Multi-Center Clinical Trials of Catuso Biantine Gastric Cancer will open the world's first T cell engager bispecific antibody drug, Cardoso, which has recently been approved by clinical trials of NMPA, MOHW and MFDS for the expansion of gastric cancer indications and a new clinical journey.
Drug Approval: Bollinger Ingerheim nintedanib has been approved by the European Union for the treatment of PF-ILD Bollinger Ingerheim, whose anti-pulmonary fibrosis treatment drug Ofev (nintedanib, nidanib) has been approved by the European Commission for the treatment of other patients with chronic fibrosis (PF-ILD) patients with transsexual phenomesomeds.
the first type 1 hepatiterary syndrome drug was recommended by the FDA panel of experts for approval on the 15th, Mallinckrodt announced that the FDA Advisory Committee on Cardiovascular and Kidney Medicines voted (8 in favor vs 7 against) to recommend its approval for the research drug terlipressin for the treatment of liver and kidney syndrome type 1 (HRS-1) in adults.
Dire Medical 2 medical device products by the European Union CE certification 16, Dilley Medical issued a notice that the company's 2 medical device products (probe conditioning fluid, urine sample collector) recently obtained CE certification certificate.
Hengrui PharmaceuticalSHr-1703 injection sHR-1703 injection approval notice for drug clinical trials 15, Hengrui Pharmaceuticals issued a notice that the company recently received the State Drug Administration approved the issuance of the SHR-1703 injection of the "drug clinical trial approval notice", and will be launched in the near future clinical trials.
Fosun Pharma's new coronavirus mRNA vaccine Phase I clinical trial was approved by Star Pharma announced that the company's holding subsidiary Shanghai Fosun Pharma recently received approval from the State Drug Administration for its licensed new coronavirus mRNA vaccine (BNT162b1) for the prevention of new coronavirus pneumonia clinical trials.
Fosun Pharma intends to conduct Phase I clinical trials of the vaccine in China (excluding Hong Kong, Macao and Taiwan) when the conditions are met.
(Sina Pharmaceutical News) Qilu Pharmaceutical 4 generic drug Aripitin was approved in the recent Qilu Pharmaceutical 4 generic arigitan capsule listing application (acceptance number CYHS1800538, 539) in the NMPA status change dating "in approval", which means that the first domestic Arigitan capsule was approved in the immediate.
East Sunshine drug psychostable drug listing application was accepted recently, CDE official website shows that Guangdong East Sunshine Pharmaceuticals Fuma acid thiopine 4 class of generic listing application was accepted.
lumasiran UK approved to treat the underlying cause of primary hypergrassemia type 1, the UK Medicines and Health Products Agency has issued a positive scientific opinion on lumasiran's early access to drugs.
the decision, eligible patients with leukuric acid type 1 in the UK, many of them children, will be able to access the treatment before lumasiran is approved by the European Commission.
AXA Pharmaceuticals Bcl-2 inhibitor APG-2575 for the treatment of WM was certified by the FDA Orphan Drug on the 15th, AXA Pharmaceuticals announced that the U.S. FDA has awarded its Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of Walne polycyte protein emis (Waldenstr?m Gloglobulinemia, WM).
this is the first orphan drug qualification obtained by APG-2575, and the second orphan drug qualification from the FDA.
Research and Development Partnership: Novocure and Mercadon have entered into a partnership agreement for the treatment of non-small cell lung cancer patients Novocure, which has concluded a clinical trial cooperation agreement with Mercadon, under which Novocure and Mercado plan to conduct a Phase 2 clinical pilot study to combine the tumor treatment electric field with Mercadon's heavy anti-PD-1 therapy Keytruda to treat patients with non-small cell lung cancer.
Co-development of ROS1/NTRK dual-target inhibitors with NewG Lab in South Korea, innovative drug research and development company Yan Yuan Pharma announced that it has reached a partnership with NewG Lab Pharma in South Korea to award its next generation ROS1/NTRK inhibitortaletctinib to the South Korean market for its exclusive clinical development and commercialization interests.
.